Département de chirurgie cardiovasculaire, hôpital Européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Université de Paris, INSERM, PARCC, 75015 Paris, France.
Arch Cardiovasc Dis. 2020 Apr;113(4):285-292. doi: 10.1016/j.acvd.2020.01.002. Epub 2020 Mar 11.
Although the initial clinical trials of cardiac cell therapy have failed to demonstrate unequivocal clinical benefits, the accumulation of preclinical data gathered in parallel can now help us to understand the main causes of failures, while providing mechanistic insights that may be leveraged to improve the outcomes of subsequent clinical studies using cells or their secreted products. This review briefly describes the current status of clinical trials, discusses the potential mechanisms of action of the grafted cells, and the impact of this knowledge on the design of future studies, and finally draws some perspectives.
虽然心脏细胞治疗的初步临床试验未能显示出明确的临床益处，但现在积累的平行收集的临床前数据可以帮助我们了解失败的主要原因，同时提供可能被利用来改善使用细胞或其分泌产物的后续临床研究结果的机制见解。这篇综述简要描述了临床试验的现状，讨论了移植细胞的潜在作用机制，以及这些知识对未来研究设计的影响，最后得出了一些观点。
